This Medical Letter review compares a newly approved 2-dose hepatitis B virus vaccine that uses a synthetic oligonucleotide immunostimulatory adjuvant, and is licensed for use in adults, with other commercially available 3-dose vaccines.
No takes yet. Share an insight, caveat, or question.
A 2018 study studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: